ArticleBritish journal of clinical pharmacology2018
Drug management in acute kidney disease - Report of the Acute Disease Quality Initiative XVI meeting.
Article in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference.Kidney international · 2020 · on this mapGuideline
- What is the best dialysis regimen for severe AKI to allow kidney function recovery?Clinical kidney journal · 2026Review
- Resolution of drug-induced acute kidney injury: mechanistic assessment to guide patient care.Intensive care medicine · 2026Article
- Top ten tips to manage patients after acute kidney injury.Clinical kidney journal · 2026Review
- Acute kidney injury and postoperative delirium.Journal of biomedical research · 2025Article
- Pregnancy-associated acute kidney injury - consensus report of the 32nd Acute Disease Quality Initiative workgroup.Nature reviews. Nephrology · 2025Article
- State of the art: Renal recovery after AKI - from basic science to clinical practice.Intensive care medicine · 2025Review
- ASN Kidney Health Guidance on the Outpatient Management of Patients with Dialysis-Requiring Acute Kidney Injury.Journal of the American Society of Nephrology : JASN · 2025Article
- Unveiling the enigma of acute kidney disease: predicting prognosis, exploring interventions, and embracing a multidisciplinary approach.Kidney research and clinical practice · 2024Article
- Medication Management in the Critically Ill Patient with Acute Kidney Injury.Clinical journal of the American Society of Nephrology : CJASN · 2023Review
- Nanodrugs alleviate acute kidney injury: Manipulate RONS at kidney.Bioactive materials · 2023Review
- Pharmacy Practice Standards for Outpatient Nephrology Settings.Kidney medicine · 2022Article
- Antimicrobial Stewardship at Transitions of Care to Outpatient Settings: Synopsis and Strategies.Antibiotics (Basel, Switzerland) · 2022Review
- Consensus Obtained for the Nephrotoxic Potential of 167 Drugs in Adult Critically Ill Patients Using a Modified Delphi Method.Drug safety · 2022Article
- Bibliometric and visual analysis of nephrotoxicity research worldwide.Frontiers in pharmacology · 2022Article
- Nephrotoxin Exposure in the 3 Years following Hospital Discharge Predicts Development or Worsening of Chronic Kidney Disease among Acute Kidney Injury Survivors.American journal of nephrology · 2022Article
- Angiotensin II Receptor Blocker Associated With Less Outcome Risk in Patients With Acute Kidney Disease.Frontiers in pharmacology · 2022Article
- Development of a Theory-Informed Behavior Change Intervention to Reduce Inappropriate Prescribing of Nephrotoxins and Renally Eliminated Drugs.The Annals of pharmacotherapy · 2021Article
- Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative.Nature reviews. Nephrology · 2021Review
- Long-term kidney function of patients discharged from hospital after an intensive care admission: observational cohort study.Scientific reports · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo summarize and extend the main conclusions and recommendations relevant to drug management during acute kidney disease (AKD) as agreed at the 16
methodsUsing a modified Delphi method to achieve consensus, experts attending the 16
resultsWe recommend that medication reconciliation should occur at admission and discharge, at AKD diagnosis and change in AKD phase, and when the patient's condition changes. Strategies to avoid adverse drug reactions in AKD should seek to minimize adverse events from overdosing and nephrotoxicity and therapeutic failure from under-dosing or incorrect drug selection. Medication regimen assessment or introduction of medications during the AKD period should consider the nephrotoxic potential, altered renal and nonrenal elimination, the effects of toxic metabolites and drug interactions and altered pharmacodynamics in AKD. A dynamic monitoring plan including repeated serial assessment of clinical features, utilization of renal diagnostic tests and therapeutic drug monitoring should be used to guide medication regimen assessment.
conclusionsDrug management during different phases of AKD requires an individualized approach and frequent re-assessment. More research is needed to avoid drug associated harm and therapeutic failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.